MX2021000264A - Compuestos peptidicos y usos terapeuticos de los mismos. - Google Patents

Compuestos peptidicos y usos terapeuticos de los mismos.

Info

Publication number
MX2021000264A
MX2021000264A MX2021000264A MX2021000264A MX2021000264A MX 2021000264 A MX2021000264 A MX 2021000264A MX 2021000264 A MX2021000264 A MX 2021000264A MX 2021000264 A MX2021000264 A MX 2021000264A MX 2021000264 A MX2021000264 A MX 2021000264A
Authority
MX
Mexico
Prior art keywords
same
therapeutic uses
peptide compounds
dexamethasone
mouse
Prior art date
Application number
MX2021000264A
Other languages
English (en)
Inventor
Eran Ovadia
Avi Ben-Shimon
Original Assignee
Immunity Pharma Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Immunity Pharma Ltd filed Critical Immunity Pharma Ltd
Publication of MX2021000264A publication Critical patent/MX2021000264A/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K7/00—Peptides having 5 to 20 amino acids in a fully defined sequence; Derivatives thereof
    • C07K7/04—Linear peptides containing only normal peptide links
    • C07K7/08—Linear peptides containing only normal peptide links having 12 to 20 amino acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K7/00—Peptides having 5 to 20 amino acids in a fully defined sequence; Derivatives thereof
    • C07K7/04—Linear peptides containing only normal peptide links
    • C07K7/06—Linear peptides containing only normal peptide links having 5 to 11 amino acids
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/01—Fusion polypeptide containing a localisation/targetting motif
    • C07K2319/03—Fusion polypeptide containing a localisation/targetting motif containing a transmembrane segment

Abstract

Se desvelan péptidos aislados capaces de reducir la cantidad de pérdida de peso del bazo y/o el timo inducida por la dexametasona en el ratón así como los usos de los mismos.
MX2021000264A 2018-07-11 2019-07-10 Compuestos peptidicos y usos terapeuticos de los mismos. MX2021000264A (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
IL26055518 2018-07-11
PCT/IL2019/050774 WO2020012478A2 (en) 2018-07-11 2019-07-10 Peptide compounds and therapeutic uses of same

Publications (1)

Publication Number Publication Date
MX2021000264A true MX2021000264A (es) 2021-05-12

Family

ID=69141375

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2021000264A MX2021000264A (es) 2018-07-11 2019-07-10 Compuestos peptidicos y usos terapeuticos de los mismos.

Country Status (15)

Country Link
US (1) US11912790B2 (es)
EP (1) EP3820882A2 (es)
JP (2) JP7395517B2 (es)
KR (1) KR20210045397A (es)
CN (1) CN112351989B (es)
AU (1) AU2019300567A1 (es)
BR (1) BR112020024748A2 (es)
CA (1) CA3100961A1 (es)
CO (1) CO2021001290A2 (es)
EA (1) EA202190249A1 (es)
IL (1) IL280101A (es)
MX (1) MX2021000264A (es)
SG (1) SG11202012773QA (es)
WO (1) WO2020012478A2 (es)
ZA (1) ZA202100587B (es)

Families Citing this family (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EA202190249A1 (ru) 2018-07-11 2021-05-21 Иммунити Фарма Лтд. Пептидные соединения и их терапевтическое применение
IL272074A (en) * 2020-01-15 2021-07-29 Immunity Pharma Ltd Peptide compounds and their use in methods of treating diseases

Family Cites Families (43)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
NL154600B (nl) 1971-02-10 1977-09-15 Organon Nv Werkwijze voor het aantonen en bepalen van specifiek bindende eiwitten en hun corresponderende bindbare stoffen.
JPS4843906B1 (es) * 1970-08-11 1973-12-21
NL154598B (nl) 1970-11-10 1977-09-15 Organon Nv Werkwijze voor het aantonen en bepalen van laagmoleculire verbindingen en van eiwitten die deze verbindingen specifiek kunnen binden, alsmede testverpakking.
NL154599B (nl) 1970-12-28 1977-09-15 Organon Nv Werkwijze voor het aantonen en bepalen van specifiek bindende eiwitten en hun corresponderende bindbare stoffen, alsmede testverpakking.
US3901654A (en) 1971-06-21 1975-08-26 Biological Developments Receptor assays of biologically active compounds employing biologically specific receptors
US3853987A (en) 1971-09-01 1974-12-10 W Dreyer Immunological reagent and radioimmuno assay
US3867517A (en) 1971-12-21 1975-02-18 Abbott Lab Direct radioimmunoassay for antigens and their antibodies
NL171930C (nl) 1972-05-11 1983-06-01 Akzo Nv Werkwijze voor het aantonen en bepalen van haptenen, alsmede testverpakkingen.
US3850578A (en) 1973-03-12 1974-11-26 H Mcconnell Process for assaying for biologically active molecules
US3935074A (en) 1973-12-17 1976-01-27 Syva Company Antibody steric hindrance immunoassay with two antibodies
US3996345A (en) 1974-08-12 1976-12-07 Syva Company Fluorescence quenching with immunological pairs in immunoassays
US4034074A (en) 1974-09-19 1977-07-05 The Board Of Trustees Of Leland Stanford Junior University Universal reagent 2-site immunoradiometric assay using labelled anti (IgG)
US3984533A (en) 1975-11-13 1976-10-05 General Electric Company Electrophoretic method of detecting antigen-antibody reaction
US4098876A (en) 1976-10-26 1978-07-04 Corning Glass Works Reverse sandwich immunoassay
US4879219A (en) 1980-09-19 1989-11-07 General Hospital Corporation Immunoassay utilizing monoclonal high affinity IgM antibodies
US5011771A (en) 1984-04-12 1991-04-30 The General Hospital Corporation Multiepitopic immunometric assay
US4666828A (en) 1984-08-15 1987-05-19 The General Hospital Corporation Test for Huntington's disease
US4801531A (en) 1985-04-17 1989-01-31 Biotechnology Research Partners, Ltd. Apo AI/CIII genomic polymorphisms predictive of atherosclerosis
US5272057A (en) 1988-10-14 1993-12-21 Georgetown University Method of detecting a predisposition to cancer by the use of restriction fragment length polymorphism of the gene for human poly (ADP-ribose) polymerase
US5192659A (en) 1989-08-25 1993-03-09 Genetype Ag Intron sequence analysis method for detection of adjacent and remote locus alleles as haplotypes
US5281521A (en) 1992-07-20 1994-01-25 The Trustees Of The University Of Pennsylvania Modified avidin-biotin technique
WO1997044447A2 (en) * 1996-05-03 1997-11-27 President And Fellows Of Harvard College Transcriptional activation system, activators, and uses therefor
GB9711148D0 (en) * 1997-05-31 1997-07-23 Peptide Therapeutics Ltd Human MAFA
EP0928968A1 (en) 1998-01-12 1999-07-14 Universität Basel Screening method for apoptosis and necrosis
WO2002082044A2 (en) 2001-04-03 2002-10-17 The Board Of Trustees Of The Leland Stanford Junior University Method of imaging cell death in vivo
US20040204340A1 (en) * 2003-04-11 2004-10-14 Guilford Pharmaceuticals, Inc. Polyprolyl inhibitors of cyclophilin
EP1781315B1 (en) * 2004-08-23 2015-01-07 Yeda Research And Development Co., Ltd. Peptide inhibitors for mediating stress responses
WO2006083906A2 (en) * 2005-02-01 2006-08-10 Attenuon, Llc Compositions containing the anti-angiogenic phscn-peptide
US7704953B2 (en) * 2006-02-17 2010-04-27 Mdrna, Inc. Phage displayed cell binding peptides
US8212001B2 (en) * 2009-09-17 2012-07-03 Ramot At Tel-Aviv University Ltd. Peptides for the treatment of oxidative stress related disorders
WO2011126882A2 (en) * 2010-03-30 2011-10-13 American Type Culture Collection Therapeutic peptides and their derivatives and therapeutic uses thereof
EP2593595B1 (en) * 2010-07-16 2020-03-11 Avantgen, Inc. Novel peptides and uses thereof
EP2655612B1 (en) * 2010-12-23 2017-07-19 Shell Internationale Research Maatschappij B.V. Gene disruptants producing fatty acyl-coa derivatives
US20140088017A1 (en) 2011-05-23 2014-03-27 Yeda Research And Development Co., Ltd. Use of akt phosphorylation as a biomarker for prognosing neurodegenerative diseases and treating same
US20140271666A1 (en) * 2013-03-14 2014-09-18 Immune Pharmaceuticals Ltd. Use of anti-eotaxin antibodies for treating inflammatory bowel disease
CN104045703B (zh) * 2013-03-15 2021-04-06 深圳君圣泰生物技术有限公司 一种多肽、多肽衍生物、多肽的可药用盐及药物组合物
US8802633B1 (en) * 2013-03-18 2014-08-12 Board Of Regents, The University Of Texas System Autophagy-inducing peptide analogs
KR102569494B1 (ko) * 2014-07-15 2023-08-21 이슘 리서치 디벨롭먼트 컴퍼니 오브 더 히브루 유니버시티 오브 예루살렘 엘티디. Cd44의 단리된 폴리펩타이드 및 이의 사용
US9453061B2 (en) * 2014-08-06 2016-09-27 Brown University Method and compositions for treatment of calcineurin-related diseases
EP3286361A4 (en) 2015-04-23 2019-05-08 Nantomics, LLC CANCER NEO-EPITOPES
WO2017011338A1 (en) 2015-07-10 2017-01-19 President And Fellows Of Harvard College Sortase-mediated coupling of immunogenic polysaccharide-protein conjugates and their use
EA202190249A1 (ru) 2018-07-11 2021-05-21 Иммунити Фарма Лтд. Пептидные соединения и их терапевтическое применение
IL272074A (en) 2020-01-15 2021-07-29 Immunity Pharma Ltd Peptide compounds and their use in methods of treating diseases

Also Published As

Publication number Publication date
US11912790B2 (en) 2024-02-27
IL280101A (en) 2021-03-01
US20210261615A1 (en) 2021-08-26
JP7395517B2 (ja) 2023-12-11
BR112020024748A2 (pt) 2021-03-23
KR20210045397A (ko) 2021-04-26
JP2024026217A (ja) 2024-02-28
CO2021001290A2 (es) 2021-02-26
ZA202100587B (en) 2022-07-27
EA202190249A1 (ru) 2021-05-21
CN112351989A (zh) 2021-02-09
CN112351989B (zh) 2024-03-26
WO2020012478A3 (en) 2020-02-20
JP2021531246A (ja) 2021-11-18
CA3100961A1 (en) 2020-01-16
SG11202012773QA (en) 2021-01-28
AU2019300567A1 (en) 2021-02-25
EP3820882A2 (en) 2021-05-19
WO2020012478A2 (en) 2020-01-16

Similar Documents

Publication Publication Date Title
SA519401646B1 (ar) الجلوبولينات المناعية واستخداماتها
NZ765759A (en) Atf5 peptide variants and uses thereof
MX2019006515A (es) Composiciones que comprenden peptido wkdeagkplvk.
EP3909975A4 (en) NEW POLYPEPTIDE AND ITS THERAPEUTIC APPLICATION
EP3946410A4 (en) Therapeutic interferon alpha 1 proteins
MX2021000264A (es) Compuestos peptidicos y usos terapeuticos de los mismos.
SG11202006669RA (en) Peptides and uses thereof
EP3763731A4 (en) PARTIAL PEPTIDE HMGN AND ANTI-CANCER THERAPY USING IT
EP3882263A4 (en) GLUCAGON DERIVED PEPTIDE AND USE THEREOF
SG10201809099PA (en) Tissue protective peptides and peptide analogs for preventing and treating diseases and disorders associated with tissue damage
IL285144A (en) Medicinal peptides
GB2603645B (en) Polypeptides having anti-senescent effects and uses thereof
GB202201001D0 (en) Polypeptide and use thereof
MX2021008005A (es) Bibliotecas de peptidos y metodos de uso de las mismas.
MX2021015097A (es) Composiciones de ca2 y metodos para regulación ajustable.
AU2020234373A1 (en) Novel peptide and use thereof
MX2022008746A (es) Compuestos de peptidos y procedimientos de tratamiento de enfermedades que usan los mismos.
EP3696187A4 (en) SYNTHETIC PEPTIDE SP4 AND ITS USE
IL290520A (en) Medicinal peptides
EP3773668A4 (en) TRUNCATED CARTILE HOMING PEPTIDES AND PEPTIDE COMPLEXES AND METHODS OF USE
GB201904099D0 (en) Peptides and use thereof
AU2018275270A1 (en) Peptide PAC1 antagonists
IL290643A (en) Peptides for transport and methods of using them
IL281091A (en) Peptide therapy for cancer treatment and their uses
GB201914682D0 (en) Novel anti-cancer peptides and uses thereof